Holen Sie sich die Stockscreener-App
0.7945
2.40%
-0.0195
Handel nachbörslich:
.81
0.0155
+1.95%
Schlusskurs vom Vortag:
$0.814
Offen:
$0.83
24-Stunden-Volumen:
241.25K
Relative Volume:
0.33
Marktkapitalisierung:
$99.47M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-0.6019
EPS:
-1.32
Netto-Cashflow:
$-117.73M
1W Leistung:
-13.81%
1M Leistung:
-8.69%
6M Leistung:
-30.91%
1J Leistung:
+1.86%
1-Tages-Spanne:
$0.7809
$0.859
1-Wochen-Bereich:
$0.7809
$0.9495
52-Wochen-Spanne:
$0.6174
$1.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| KPTI | 0.7945 | 99.47M | 140.46M | -146.34M | -117.73M | -1.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm to Present New Selinexor Clinical Data at ASH 2024 Annual Meeting | KPTI Stock News - StockTitan
Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat
GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for KPTI Earnings - MarketBeat
What is HC Wainwright's Estimate for KPTI FY2024 Earnings? - MarketBeat
Karyopharm Therapeutics Falls To US$0.88, But Insiders Sold At Lower Price - Simply Wall St
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Karyopharm Therapeutics Reports Q3 2024 Financial Results and Corporate Progress - Defense World
Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2024 Earnings Call Transcript - Insider Monkey
Karyopharm stock price target raised, overweight on revenue beat - Investing.com India
Karyopharm therapeutics CEO Richard Paulson sells $3,346 in stock - Investing.com
Karyopharm therapeutics CEO Richard Paulson sells $3,346 in stock By Investing.com - Investing.com Canada
Karyopharm stock price target raised, overweight on revenue beat By Investing.com - Investing.com Australia
Earnings call: Karyopharm Therapeutics reports on clinical and financial progress - Investing.com Nigeria
Piper Sandler Boosts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00 - MarketBeat
Karyopharm price target raised to $5 from $4 at Piper Sandler - TipRanks
Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlig - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com Australia
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... - Yahoo Finance
Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings - TipRanks
Karyopharm Therapeutics Q3 2024 Earnings Preview - MSN
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - AOL
Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings: EPS Loss of - GuruFocus.com
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Tuesday - MarketBeat
Karyopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC Wainwright - MarketBeat
Karyopharm updates SENTRY trial endpoints, eyes 2025 data - Investing.com India
Karyopharm updates SENTRY trial endpoints, eyes 2025 data By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm stock gains as late-stage trial changes (KPTI:NASDAQ) - Seeking Alpha
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 - StockTitan
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis - Kilgore News Herald
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):